|1.||Melanoma (Melanoma, Malignant)
10/01/1980 - "A phase II study of chlorozotocin in metastatic malignant melanoma."
06/01/1982 - "Seventy-nine patients with metastatic melanoma received chlorozotocin (150 mg/m2) every 6 weeks. "
07/01/1981 - "Phase II evaluation of chlorozotocin in patients with malignant melanoma."
10/01/1980 - "These data suggest that chlorozotocin should be evaluated in combination with other agents active against melanoma."
10/01/1980 - "Chlorozotocin is active against metastatic melanoma to the same degree as other chloroethylnitrosoureas in clinical use, but without causing bone marrow toxicity. "
11/15/1989 - "Chlorozotocin (CLZ), a nitrosourea synthesized in the hope that it would have little bone marrow toxicity, has been shown to be effective against animal tumors and tumor cells in culture. "
11/15/1989 - "Ability of the alpha and beta anomers of chlorozotocin to kill rat 9L tumor cells in vitro."
01/01/1986 - "Chlorozotocin is a chloroethylnitrosourea antitumor agent that is in clinical trial for a variety of human tumors. "
04/01/1985 - "The effect of chlorozotocin [(CZT) CAS: 54749-90-5; 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-gluco-pyranose] was studied on a series of tumor cells, cultured or extracted fresh primary or transplanted tumors, by means of clonogenic assay. "
03/01/1981 - "Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer."
07/01/1982 - "In view of the comparable therapeutic activity of the three drugs for L1210 leukemia, therapeutic efficacy does not appear to be impaired by the increased rate of adduct removal observed with chlorozotocin in this system."
01/01/1980 - "In the L1210 leukemia system, chlorozotocin has curative activity at doses that result in minimal bone marrow toxicity. "
05/01/1979 - "Comparative screening against leukemia L1210 with concurrent toxicity controls revealed no significant difference between D- and L-chlorozotocin in either activity or toxicity."
01/01/1983 - "Comparison of the transport of chlorozotocin and CCNU in L1210 leukemia and murine bone marrow cells in vitro."
07/01/1981 - "A rationale based on known chemical, biochemical, and biologic properties of nitrosoureas led to the testing of combinations of CCNU with chlorozotocin for in vivo activity against L1210 leukemia. "
|4.||Stomach Neoplasms (Stomach Cancer)
05/15/1983 - "The effect of sequential addition of the nitrosourea, chlorozotocin, to the FAM combination in advanced gastric cancer."
01/01/1980 - "Chlorozotocin is now undergoing phase II evaluation in combination chemotherapy trials in colon and stomach cancer."
05/15/1983 - "Twenty-three patients with advanced measurable gastric cancer were treated with FAM-chlorozotocin in an attempt to demonstrate improvement in rate and duration of response over FAM (5-fluorouracil, Adriamycin and mitomycin C). "
|5.||Colorectal Neoplasms (Colorectal Cancer)
08/01/1981 - "Phase II trial with chlorozotocin in advanced colorectal cancer."
01/01/1981 - "Phase II study of chlorozotocin in the treatment of advanced colorectal cancer."
01/01/1984 - "Chlorozotocin has minimal activity against colorectal carcinomas and no dose-response relationship is evident."
01/01/1984 - "Chlorozotocin: results in colorectal carcinoma treated with high and low doses. "
01/01/1981 - "Chlorozotocin is not effective against colorectal cancer when used as a single agent given as an iv bolus at doses of 120 mg/m2 (30 patients) and 150 mg/m2 (nine patients). "
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|3.||Combination Drug Therapy (Combination Chemotherapy)